Attention Deficit Hyperactivity Disorder: A Comparison of Medication Efficacy and Cost
According to the United States Surgeon General, 1 approximately 20% of children and adolescents in the United States (U.S.) exhibit signs or symptoms of a psychological or behavioral disorder. 2 Attention Deficit Hyperactivity Disorder (ADHD) is one of the more common childhood psychological disorders affecting three to seven percent of school-age children. 3 ADHD often presents in early childhood with symptoms of hyperactivity, impulsivity, and/or inattention. 4, 5 Associated with a variety of complications, untreated ADHD has the potential to impair a child's cognitive, academic, behavioral, emotional, and social functioning. 4, 6 With full implementation of the Patient Protection and Affordable Care Act (PPACA) on January 1, 2014, 7 health insurance coverage is anticipated to assist an additional 32 million previously uninsured citizens, thereby reducing the total number of uninsured in the U.S. 8 and achieving near-universal coverage. 7 A portion of the PPACA is designed to expand the eligibility for Medicaid by 15 million Americans, limit insurance exclusions, and mandate employers or individuals to purchase health insurance. 9, 7 While the PPACA alters health care coverage for many, it does not achieve universal coverage. 9 In fact, it has been estimated that 24 million people will remain without health insurance coverage, even after January 1, 2014. 7 This number could be higher, though, depending on how many states implement the Medicaid expansion program. 10 In addition, "adults with incomes of 250-400 percent of poverty could remain at risk for…premiums that are high relative to their incomes." 11 Unfortunately, obtaining ADHD medication can be a costly endeavor for the family with an ADHD child, especially if the family is either uninsured or underinsured. Between 1994 and
2003, the price of ADHD medications in the U.S. rose by 285%. 12 Considering the ever increasing costs of ADHD medications, "…providers and consumers should consider the costeffectiveness of a medication when making decisions about drug acceptance and coverage." 12 Moreover, because untreated children with ADHD may suffer social, behavioral, and emotional consequences; healthcare providers (HCPs) must carefully assess ADHD medication costs and efficacy to meet the needs of the child and family. The purpose of this review, therefore, is to evaluate ADHD medications to promote effective management of pediatric patients in relation to efficacy and expense.
METHOD
Several electronic database searches were conducted to review studies related to medications and treatments for ADHD. Articles published in the past 10 years in English were included for review. Other inclusion criteria encompassed age groups related to children and adolescents, ages 0-18, and research articles using human studies. Systematic and integrative reviews of randomized controlled studies and drug trials related to ADHD were also obtained. While effective management of ADHD may incorporate behavioral, pharmacological, and multimodal approaches, only pharmacological treatment options were included for review. Articles which focused on adult treatment of ADHD or articles of ADHD diagnoses attached to other comorbidities such as psychiatric or cardiac issues were also excluded. Search terms included:
ADHD, Attention Deficit Hyperactivity Disorder, medication, efficacy, cost, pediatric, treatment, effectiveness, safety, side effects, expense, children, adolescent, drug therapy, and risk.
RESULTS

Stimulants
Stimulants are the first-line treatment option for 75-90% of children suffering with the hyperactivity, impulsivity, and inattention of ADHD. [13] [14] [15] [16] 24 The liquid form of methylphenidate (Methylin) costs $291.00 for 300 ml of the 10 mg/5 ml dose.
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Dexmethylphenidate. Focalin is the common brand name for dexmethylphenidate, a tablet that is also available as a generic. Like Zenzedi (dextroamphetamine), dexmethylphenidate is available in smaller doses starting at 2.5 mg tablets and increasing in dosing to 5 mg and 10 mg tablets. 13, 27 Dexmethylphenidate is also approved for use in children 6 years of age or older. Long-acting stimulants. Long-acting stimulants are typically taken only once a day and have a duration ranging from 6-12 hours. 23 As with all extended release medications, the pills or capsules should not be divided, crushed or chewed. 24 The long-acting stimulants have the most variety regarding route of administration, including tablets, capsules, liquid, and a transdermal patch. All of the long-acting stimulants are FDA approved for use in children who are 6 years and older. 25 A list of long-acting stimulants, available doses, and associated costs can be found in Table 3 .
Dextroamphetamine. The brand name preparation of dextroamphetamine ER is Dexedrine Spansules and is available as capsules in 5 mg, 10 mg, and 15 mg doses. For children who find it difficult to swallow a capsule, dextroamphetamine ER can be opened and sprinkled over a small amount of applesauce as long as the beads are not chewed or crushed. 13 The cost for 
Non-stimulants
Generally, non-stimulants are not considered first-line ADHD interventions 13,22,16 ; however, for patients who fail to respond to stimulants, for whom stimulants are contraindicated, or for patients in whom other comorbidities exist (e.g. tic disorder), a non-stimulant may be a viable treatment option. 13, 22, 16 Non-stimulant treatment options for ADHD include atomoxetine (Strattera) which is a norepinephrine reuptake inhibitor and guanfacine (Intuniv) and clonidine ER (Kapvay) which are both alpha-2 adrenergic agonists. While each of the non-stimulant medications are FDA approved for use in children aged 6 years and older, the AAP recommends a stepwise treatment of atomoxetine, guanfacine and then clonidine ER, in that specific order. 29 One disadvantage of non-stimulant ADHD medications is that achieving a therapeutic response takes time, sometimes several weeks before improvement is seen, whereas stimulants act quickly and results may be perceived to be immediate. 30 A list of non-stimulants, available doses, and associated costs can be found in Table 4 .
Norepinephrine reuptake inhibitors. Atomoxetine is the generic form of Strattera, which is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg doses. The capsules may be administered as a one-time morning dose or as divided doses in the morning and late afternoon or early evening. 24, 27 The duration of atomoxetine is approximately 10-12 hours. 13 The lowest dose, 10 mg, can be purchased for $240.44 for 30 capsules. should only be prescribed after failing on a trial of atomoxetine. 29 The duration of guanfacine is at least a 10-12 hour duration and is recommended as a once daily medication taken in either the morning or evening. 25 The price of guanfacine is $16.50 for 30 tablets of the lowest dose, 1 mg.
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Clonidine ER can be prescribed as 0.1 mg or 0.2 mg tablets and has a duration of at least 10-12 hours. While clonidine ER is FDA approved as a non-stimulant treatment option, a trial should be attempted only after the patient has first failed on atomoxetine and guanfacine. 29 The lowest dose of clonidine ER, 0.1 mg, can be purchased for $141.60 for 30 tablets.
IMPLICATIONS FOR PRACTICE
While there are no intermediate-or long-acting ADHD medications approved for use in preschool-aged children aged 3-5 years, there are two main classes of short-acting ADHD medications that have received approval from the FDA for use in this age group, namely dextroamphetamine and dextroamphetamine/amphetamine. 27 However, despite the FDA's approval, the American Academy of Pediatrics (AAP) does not recommend the use of dextroamphetamine or dextroamphetamine/amphetamine in preschool-aged children 29 with the rationale that the FDA approval of these ADHD medications in children younger than 6 years old took place during a time when less stringent criteria was required. Thus, even though dextroamphetamine and dextroamphetamine/amphetamine have FDA approval for use in children as young as 3 years old, the empirical evidence regarding the safety and efficacy of these short-acting stimulants in preschoolers is lacking. 29 Most of the stimulant medication studies in preschoolers with ADHD have been conducted with methylphenidate, a medication proven to be safe and efficacious in preschool children. Notwithstanding the recommendation to use methylphenidate off-label in preschool children with ADHD, its use is recommended in children 4-5 years old and after trying behavior interventions first. 13, 29 According to Krull 13 , children suffering from ADHD who are younger than 6 years old should also be managed by or in consultation with a specialist.
Recommendations for Preschoolers with ADHD
Three-year old children are difficult to diagnose and have limited options for stimulant medications. 29 Thus, we recommend the diagnosis and management of 3 year old children with ADHD in coordination with a specialist. Because methylphenidate has been well studied and is recommended in guidelines set forth by the AAP for ADHD treatment in preschoolers ages 4-5 years old, we cautiously recommend its use as a first-line stimulant medication in this age group.
Besides being recommended as the first-line stimulant medication for children ages 4-5, it is also the most cost-effective option of all the short-acting stimulants. The lowest available dose, however, is a 5 mg tablet that is unscored, meaning that it may not accurately split with a pill splitter. Thus, methylphenidate should be prescribed in 4-5 year old preschoolers only when the 5 mg dose can be swallowed whole.
Recommendations for Children Unable to Swallow Pills
Children over the age of 6 years who are unable to swallow pills whole should be provided other options. Among the short-acting stimulants, the most cost-effective option is methylphenidate (Methylin) chewable tablets at $268.80 for 60 5 mg tablets. Non-tablet options, however, are unavailable in the intermediate-acting stimulant category. If a long-acting stimulant is clinically indicated, the most cost-effective option is dextroamphetamine ER, which is a capsule that can be opened and sprinkled over applesauce.
Recommendations for Short-, Intermediate-, and Long-acting Stimulants
Since there is no clear difference in efficacy of short-, intermediate-, and long-acting stimulants, cost should be an important factor when selecting a stimulant medication for children age 6 years and older. The most cost-effective short-acting stimulant is methylphenidate (Ritalin) 
Recommendations for Non-stimulants
While guanfacine is the most cost-effective option for non-stimulant treatment of ADHD, it is not the first-line non-stimulant medication as recommended by the AAP. While cost is an important consideration, our recommendation for non-stimulant medications is primarily based on AAP guidelines. 29 
